A Phase II/III Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients With Greater Than or Equal to 0.5 cm and Less Than or Equal to 2 cm Residual Disease Following Surgery

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed stage III ovarian epithelial or primary
peritoneal cancer with residual disease no greater than 2 cm following cytoreductive
surgery The following cell types are eligible: Serous adenocarcinoma, mucinous
adenocarcinoma, clear cell adenocarcinoma, transitional cell, adenocarcinoma NOS,
endometrioid adenocarcinoma, mixed epithelial carcinoma, or peritoneal serous papillary
carcinoma Total abdominal hysterectomy with salpingo-oophorectomy or supracervical
hysterectomy, omentectomy, tumor reduction, lymph node assessment, and debulking if nodes
2 cm or greater No endometrial malignancy treated with supracervical hysterectomy No
cytologically positive pleural effusion No tumors of borderline histology No cancer of the
fallopian tubes

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 80-100% Life
expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3
Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 times upper limit
of normal (ULN) SGOT no greater than 2 times ULN Alkaline phosphatase no greater than 2
times ULN Renal: Creatinine no greater than 2 mg/dL Glomerular filtration rate no less
than 30 Other: HIV negative Not pregnant or nursing Fertile patients must use effective
contraception No other serious medical condition No other prior malignancies except
carcinoma in situ of the cervix, nonmelanomatous skin cancer, Dukes A colorectal cancer
from which patient has been disease free for past 5 years, or stage I or II breast cancer
from which patient has been disease free for past 10 years

PRIOR CONCURRENT THERAPY: Biologic therapy: Concurrent cytokine therapy allowed
Chemotherapy: No more than 1 prior chemotherapy course for ovarian or peritoneal cancer At
least 10 years since prior adjuvant chemotherapy for breast cancer Endocrine therapy: At
least 3 months since prior systemic corticosteroid or other immunosuppressive therapy
Concurrent female hormonal replacement allowed Radiotherapy: No prior radiotherapy for
ovarian or peritoneal cancer No prior radiotherapy to abdomen Surgery: Prior surgery
allowed Other: No other concurrent investigational drugs